Swedish Orphan Biovitrum AB
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Guido Oelkers
- Full Time Employees
- 1,888
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Norra Stationsgatan 93A Stockholm AB Sweden 171 65
- IPO Date
- Sep 15, 2006
- Website
- sobi.com
- Similar Companies
- Business
- Swedish Orphan Biovitrum AB (publ) (Sobi) is a Sweden-based biopharmaceutical company headquartered in Stockholm and founded in 2001 that specializes in developing, manufacturing and commercializing innovative therapies for rare diseases, with a primary focus on haematology, immunology and specialty care; its core products and services include Elocta and Alprolix for haemophilia A and B treatment, Doptelet (avatrombopag) for immune thrombocytopenia and chemotherapy-induced thrombocytopenia, Kineret (anakinra) for rare inflammatory disorders including systemic juvenile idiopathic arthritis and recurrent pericarditis, Gamifant (emapalumab) for primary haemophagocytic lymphohistiocytosis, Synagis (palivizumab) for respiratory syncytial virus prevention in high-risk infants, Orfadin, Ammonaps and Ammonul for genetic and metabolic disorders, as well as partner products encompassing around 40 specialty pharmaceuticals in haematology, oncology and emergency care, and manufacturing services for recombinant proteins such as ReFacto/Xyntha under agreement with Pfizer. Sobi operates across Europe, North America and other international markets through subsidiaries in countries including Sweden, Denmark, Finland, Norway, the United Kingdom, France and the United States, targeting patients with orphan and niche conditions in inflammation, genetics, metabolism and supportive care segments. Recent developments include a revised 2025 full-year outlook announced in October 2025 projecting low double-digit revenue growth at constant exchange rates and mid-to-high 30s adjusted EBITA margin, driven by strong year-to-date performance from Doptelet and Gamifant alongside cost efficiencies from organizational realignments; regulatory filings for label expansions such as Gamifant in secondary haemophagocytic lymphohistiocytosis and secondary HLH, Aspaveli (pegcetacoplan) in nephrology, NASP for acute graft-versus-host disease with mid-2026 FDA review, and CEL212; progression of phase 2/3 trials for Bonviva (vorasidenib) in VEXUS syndrome following FDA IND clearance; and the 2023 acquisition of CTI BioPharma to bolster its haematology portfolio.
Company News
Earnings Preview: Swedish Orphan Biovitrum (BIOVF) Q3 Earnings Expected to Decline
Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Change in number of shares and votes in Sobi
Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Sees Large Decline in Short Interest
Sobi to present clinical data on Gamifant® at Histiocyte Society 2026 in Rotterdam
Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Short Interest Update
Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)
Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)
Sobi to present new data on pegcetacoplan at ERA 2026
Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout
Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout
Swedish Orphan Biovitrum AB (publ) (SWOBY) Q1 2026 Earnings Call Transcript
EMA validates indication extension application for Tryngolza® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
Results from EMBRACE Phase 2a study of emapalumab in interferon-gamma-driven sepsis presented at ISICEM
Swedish Orphan Biovitrum AB (publ) (SWOBY) Analyst/Investor Day Transcript
Sobi Capital Markets Day 2026: Bringing brilliant ideas to life and building the next chapter with ambition to deliver SEK 55bn by 2030
Sobi Capital Markets Day 2026: Bringing brilliant ideas to life and building the next chapter with ambition to deliver SEK 55bn by 2030
Swedish Orphan Biovitrum AB (publ) (SWOBY) Q4 2025 Earnings Call Transcript
Sobi Q4 and FY 2025 report: Closing the year with significant growth and strategic progress